

Title (en)  
PHARMACEUTICALLY ACTIVE COMPOUNDS

Title (de)  
ISOFLAVON-PEPTID KONJUGATE UND DEREN VERWENDUNG

Title (fr)  
COMPOSÉS PHARMACEUTIQUEMENT ACTIFS

Publication  
**EP 2137207 A2 20091230 (DE)**

Application  
**EP 08706741 A 20080110**

Priority  
• DE 2008000040 W 20080110  
• DE 102007002386 A 20070110

Abstract (en)  
[origin: CA2675029A1] The invention relates to pharmaceutically active compounds comprising an isoflavone or isoflavone glycoside and an amino acid, peptide, or peptide derivative that is covalently bonded thereto, the peptide or peptide derivative containing 2 to 5 amino acids, as well as pharmaceutically acceptable salts or solvates of said compounds. Also disclosed are uses of such substances for producing pharmaceutical compositions, especially for the treatment of platelet aggregation and for tumor therapy. The invention can thus be used in the medical field and in the pharmaceutical industry. The compounds according to the invention are of general formula X-Pep, wherein X represents an isoflavone or isoflavone glycoside and Pep represents an amino acid or a peptide or peptide derivative containing 2 to 5 amino acids. X and Pep are covalently bonded or are linked by means of a linker system.

IPC 8 full level  
**C07K 5/06** (2006.01); **A61K 31/352** (2006.01); **A61K 31/7048** (2006.01); **A61K 38/05** (2006.01); **A61K 38/06** (2006.01); **A61K 38/07** (2006.01); **A61K 38/08** (2006.01); **A61K 47/48** (2006.01); **A61P 3/00** (2006.01); **A61P 7/02** (2006.01); **A61P 19/00** (2006.01); **A61P 35/00** (2006.01); **C07K 5/08** (2006.01); **C07K 5/10** (2006.01); **C07K 7/06** (2006.01)

CPC (source: EP US)  
**A23K 20/121** (2016.05 - EP US); **A23K 20/147** (2016.05 - EP US); **A61K 47/542** (2017.07 - EP US); **A61K 47/64** (2017.07 - EP US); **A61P 3/00** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **C07H 17/07** (2013.01 - EP US); **C07K 5/06113** (2013.01 - EP US); **C07K 5/0819** (2013.01 - EP US); **C07K 5/1021** (2013.01 - EP US); **C07K 7/06** (2013.01 - EP US); **C07K 9/001** (2013.01 - EP US); **A23V 2002/00** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US)

Citation (search report)  
See references of WO 2008083678A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**DE 102007002386 A1 20080717**; AU 2008204631 A1 20080717; CA 2675029 A1 20080717; EP 2137207 A2 20091230; JP 2010515695 A 20100513; US 2010048921 A1 20100225; WO 2008083678 A2 20080717; WO 2008083678 A3 20081113

DOCDB simple family (application)  
**DE 102007002386 A 20070110**; AU 2008204631 A 20080110; CA 2675029 A 20080110; DE 2008000040 W 20080110; EP 08706741 A 20080110; JP 2009545063 A 20080110; US 52277008 A 20080110